Trillium Asset Management LLC Cuts Stock Holdings in Gilead Sciences, Inc. $GILD

Trillium Asset Management LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 102,516 shares of the biopharmaceutical company’s stock after selling 2,640 shares during the period. Trillium Asset Management LLC’s holdings in Gilead Sciences were worth $11,366,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Activest Wealth Management boosted its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. GoalVest Advisory LLC lifted its holdings in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences during the second quarter worth $27,000. Putney Financial Group LLC lifted its holdings in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares during the period. Finally, Colonial Trust Advisors lifted its holdings in Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. BMO Capital Markets lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Truist Financial reaffirmed a “buy” rating and set a $145.00 price target (up previously from $127.00) on shares of Gilead Sciences in a research report on Monday. Wolfe Research increased their price target on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $125.08.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $123.00 on Wednesday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $124.61. The firm has a market cap of $152.62 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 0.81 and a beta of 0.34. The business’s fifty day moving average is $115.98 and its 200 day moving average is $111.92.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the previous year, the company posted $2.02 EPS. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 71,500 shares of company stock worth $8,336,040. 0.27% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.